Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887070 | 0.89 | STS (0.40) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735000 | 0.86 | GPR119 (0.41) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735601 | 0.85 | GPR119 (0.42) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735497 | 0.83 | MAPT (0.39) | ALDH2ALDH1A1GPR119KDM4EMAPT | |
| SCHEMBL14735244 | 0.83 | MEN1 (0.37) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735473 | 0.82 | MEN1 (0.47) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14734959 | 0.82 | MMP2 (0.41) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735273 | 0.80 | PDE4B (0.50) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735402 | 0.80 | CHRM2 (0.38) | STSMEN1KMT2APDE4BPDE4A | |
| SCHEMBL14735393 | 0.80 | GPR119 (0.43) | STSMEN1KMT2APDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | ALDH2 1576/4885STS 3492/4885MEN1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.